vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and KFORCE INC (KFRC). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $330.4M, roughly 1.8× KFORCE INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 2.4%, a 38.4% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs 0.1%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-7.4M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -3.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
EXEL vs KFRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $330.4M |
| Net Profit | $244.5M | $7.9M |
| Gross Margin | 95.6% | 27.3% |
| Operating Margin | 39.3% | 3.6% |
| Net Margin | 40.8% | 2.4% |
| Revenue YoY | 5.6% | 0.1% |
| Net Profit YoY | 74.8% | -2.7% |
| EPS (diluted) | $0.89 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $330.4M | ||
| Q4 25 | $597.8M | $332.0M | ||
| Q3 25 | $568.3M | $332.6M | ||
| Q2 25 | $555.4M | $334.3M | ||
| Q1 25 | $566.8M | $330.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | $539.5M | $353.3M | ||
| Q2 24 | $637.2M | $356.3M |
| Q1 26 | $244.5M | $7.9M | ||
| Q4 25 | $193.6M | $5.2M | ||
| Q3 25 | $184.8M | $11.1M | ||
| Q2 25 | $159.6M | $10.4M | ||
| Q1 25 | $139.9M | $8.1M | ||
| Q4 24 | — | $11.1M | ||
| Q3 24 | $118.0M | $14.2M | ||
| Q2 24 | $226.1M | $14.2M |
| Q1 26 | 95.6% | 27.3% | ||
| Q4 25 | 96.9% | 27.2% | ||
| Q3 25 | 96.6% | 27.7% | ||
| Q2 25 | 96.5% | 27.1% | ||
| Q1 25 | 96.5% | 26.7% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | 96.8% | 27.9% | ||
| Q2 24 | 97.2% | 27.8% |
| Q1 26 | 39.3% | 3.6% | ||
| Q4 25 | 39.6% | 2.6% | ||
| Q3 25 | 37.6% | 4.5% | ||
| Q2 25 | 33.6% | 4.5% | ||
| Q1 25 | 28.8% | 3.5% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | 25.2% | 5.3% | ||
| Q2 24 | 43.3% | 5.5% |
| Q1 26 | 40.8% | 2.4% | ||
| Q4 25 | 32.4% | 1.6% | ||
| Q3 25 | 32.5% | 3.3% | ||
| Q2 25 | 28.7% | 3.1% | ||
| Q1 25 | 24.7% | 2.5% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | 21.9% | 4.0% | ||
| Q2 24 | 35.5% | 4.0% |
| Q1 26 | $0.89 | $0.46 | ||
| Q4 25 | $0.69 | $0.29 | ||
| Q3 25 | $0.65 | $0.63 | ||
| Q2 25 | $0.55 | $0.59 | ||
| Q1 25 | $0.47 | $0.45 | ||
| Q4 24 | — | $0.60 | ||
| Q3 24 | $0.40 | $0.75 | ||
| Q2 24 | $0.77 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $117.4M |
| Total Assets | $2.8B | $384.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | $1.3M | ||
| Q4 25 | $988.5M | $2.1M | ||
| Q3 25 | $791.1M | $1.3M | ||
| Q2 25 | $1.0B | $2.5M | ||
| Q1 25 | $1.1B | $444.0K | ||
| Q4 24 | — | $349.0K | ||
| Q3 24 | $1.2B | $127.0K | ||
| Q2 24 | $1.0B | $110.0K |
| Q1 26 | $2.2B | $117.4M | ||
| Q4 25 | $2.2B | $124.6M | ||
| Q3 25 | $2.0B | $132.1M | ||
| Q2 25 | $2.1B | $134.4M | ||
| Q1 25 | $2.2B | $138.0M | ||
| Q4 24 | — | $154.6M | ||
| Q3 24 | $2.3B | $167.4M | ||
| Q2 24 | $2.1B | $166.6M |
| Q1 26 | $2.8B | $384.8M | ||
| Q4 25 | $2.8B | $365.6M | ||
| Q3 25 | $2.7B | $374.2M | ||
| Q2 25 | $2.8B | $373.6M | ||
| Q1 25 | $2.9B | $368.2M | ||
| Q4 24 | — | $357.8M | ||
| Q3 24 | $3.0B | $369.9M | ||
| Q2 24 | $2.8B | $362.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | $-7.4M |
| FCF MarginFCF / Revenue | 55.5% | -2.2% |
| Capex IntensityCapex / Revenue | 0.2% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $19.7M | ||
| Q3 25 | $49.0M | $23.3M | ||
| Q2 25 | $211.4M | $18.4M | ||
| Q1 25 | $240.3M | $249.0K | ||
| Q4 24 | — | $21.8M | ||
| Q3 24 | $271.3M | $31.0M | ||
| Q2 24 | $119.5M | $20.9M |
| Q1 26 | $332.4M | $-7.4M | ||
| Q4 25 | $288.8M | $16.7M | ||
| Q3 25 | $46.2M | $19.8M | ||
| Q2 25 | $208.5M | $14.2M | ||
| Q1 25 | $236.3M | $-3.9M | ||
| Q4 24 | — | $20.9M | ||
| Q3 24 | $263.1M | $27.5M | ||
| Q2 24 | $113.0M | $17.8M |
| Q1 26 | 55.5% | -2.2% | ||
| Q4 25 | 48.3% | 5.0% | ||
| Q3 25 | 8.1% | 6.0% | ||
| Q2 25 | 37.5% | 4.3% | ||
| Q1 25 | 41.7% | -1.2% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | 48.8% | 7.8% | ||
| Q2 24 | 17.7% | 5.0% |
| Q1 26 | 0.2% | 1.0% | ||
| Q4 25 | 0.2% | 0.9% | ||
| Q3 25 | 0.5% | 1.1% | ||
| Q2 25 | 0.5% | 1.2% | ||
| Q1 25 | 0.7% | 1.3% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 1.5% | 1.0% | ||
| Q2 24 | 1.0% | 0.9% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 3.82× | ||
| Q3 25 | 0.27× | 2.11× | ||
| Q2 25 | 1.32× | 1.76× | ||
| Q1 25 | 1.72× | 0.03× | ||
| Q4 24 | — | 1.97× | ||
| Q3 24 | 2.30× | 2.18× | ||
| Q2 24 | 0.53× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
KFRC
Segment breakdown not available.
